Two-Year Follow-Up study tests gut disease Drug's staying power

NCT ID NCT07222189

Not yet recruiting Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study aims to learn about the long-term safety and effectiveness of an investigational drug called balinatunfib for adults with Crohn's disease or ulcerative colitis. It will follow about 325 people who have already completed a previous 1-year study with this medication. The main goal is to see how well people tolerate the drug and whether it continues to help control their inflammatory bowel disease over an additional 2 years of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.